[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO2021008696A2 - Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor - Google Patents

Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor

Info

Publication number
CO2021008696A2
CO2021008696A2 CONC2021/0008696A CO2021008696A CO2021008696A2 CO 2021008696 A2 CO2021008696 A2 CO 2021008696A2 CO 2021008696 A CO2021008696 A CO 2021008696A CO 2021008696 A2 CO2021008696 A2 CO 2021008696A2
Authority
CO
Colombia
Prior art keywords
tumor
antigen
act
binding agonist
agonist molecules
Prior art date
Application number
CONC2021/0008696A
Other languages
English (en)
Inventor
Christian Klein
Ekkehard Moessner
Pablo Umaña
Thomas Hofer
Johannes Sam
Ralf Hosse
Tanja Fauti
Stephan Gasser
Guy Georges
Jenny Tosca Thom
Jean-Baptiste Pierre Vallier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2021008696A2 publication Critical patent/CO2021008696A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a moléculas biespecíficas agonistas de unión al antígeno que actúan sobre el tumor caracterizadas por la unión monovalente a CD28, métodos para su producción, composiciones farmacéuticas que contienen estos anticuerpos, y métodos para su uso.
CONC2021/0008696A 2018-12-21 2021-07-01 Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor CO2021008696A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18215121 2018-12-21
EP19187709 2019-07-23
EP19196006 2019-09-06
PCT/EP2019/086143 WO2020127618A1 (en) 2018-12-21 2019-12-19 Tumor-targeted agonistic cd28 antigen binding molecules

Publications (1)

Publication Number Publication Date
CO2021008696A2 true CO2021008696A2 (es) 2021-07-19

Family

ID=69063769

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0008696A CO2021008696A2 (es) 2018-12-21 2021-07-01 Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor

Country Status (18)

Country Link
US (2) US11608376B2 (es)
EP (1) EP3898682A1 (es)
JP (3) JP2022514343A (es)
KR (1) KR20210108981A (es)
CN (2) CN113286821A (es)
AU (1) AU2019410073B2 (es)
CA (1) CA3123493A1 (es)
CL (3) CL2021001603A1 (es)
CO (1) CO2021008696A2 (es)
CR (1) CR20210326A (es)
IL (1) IL283811A (es)
MA (1) MA54513A (es)
MX (1) MX2021007320A (es)
MY (1) MY198034A (es)
PE (1) PE20211696A1 (es)
SG (1) SG11202105093RA (es)
UA (1) UA128001C2 (es)
WO (1) WO2020127618A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CA3039446A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
AR114284A1 (es) 2018-04-13 2020-08-12 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
MY194642A (en) 2018-12-21 2022-12-09 Hoffmann La Roche Antibodies binding to cd3
KR20220025848A (ko) * 2019-06-26 2022-03-03 에프. 호프만-라 로슈 아게 Cea 및 4-1bbl에 결합하는 항체의 융합
PE20220394A1 (es) * 2019-07-31 2022-03-18 Hoffmann La Roche Anticuerpos que se fijan a gprc5d
CR20220637A (es) 2020-06-19 2023-01-31 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
WO2021255146A1 (en) * 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
EP4214234A1 (en) * 2020-09-18 2023-07-26 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof
AU2021369835A1 (en) * 2020-10-30 2023-06-01 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
AU2021374803A1 (en) * 2020-11-03 2023-06-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
TW202242121A (zh) 2021-01-11 2022-11-01 美商薩那生物科技公司 靶向cd8之病毒載體之用途
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
US20240344083A1 (en) 2021-08-04 2024-10-17 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN118696062A (zh) * 2022-02-16 2024-09-24 上海优替济生生物医药有限公司 人源化抗cd28抗体及其与抗cd40的双特异性抗体
WO2023164627A1 (en) * 2022-02-24 2023-08-31 Xencor, Inc. Anti-cd28 x anti-msln antibodies
IL314916A (en) 2022-03-07 2024-10-01 Novimmune Sa Bispecific CD28 antibodies for targeted T cell activation
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
EP4249510A1 (en) * 2022-03-22 2023-09-27 Stealth IO Novel formats of anti-cd28/spd-1 fusion constructs
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
TW202413416A (zh) * 2022-04-11 2024-04-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｅｇｆｒ和ｃｄ２８的抗原結合分子及其醫藥用途
CN115724986B (zh) * 2022-07-11 2024-07-19 惠和生物技术(上海)有限公司 三特异性抗体及其用途
WO2024018069A1 (en) * 2022-07-22 2024-01-25 Philogen S.P.A Anti-cd28 antibodies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024036207A2 (en) * 2022-08-11 2024-02-15 University Of Florida Research Foundation, Incorporated Rabbit monoclonal antibodies targeting multiple myeloma cell surface antigens
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024084052A1 (en) 2022-10-21 2024-04-25 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
WO2024148107A2 (en) * 2023-01-04 2024-07-11 Promab Biotechnologies, Inc. Epcam-cd3 epsilon bispecific antibodies
JP2024115998A (ja) 2023-02-15 2024-08-27 ニデックプレシジョン株式会社 カメラ装置
CN116715773B (zh) * 2023-02-28 2024-03-01 星奕昂(上海)生物科技有限公司 一种靶向5t4的抗体及其应用
WO2024196877A1 (en) * 2023-03-22 2024-09-26 University Of Florida Research Foundation, Incorporated Rabbit monoclonal antibodies targeting acute myeloid leukemia antigens

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186567A (en) 1977-04-18 1980-02-05 Hitachi Metals, Ltd. Ornament utilizing rare earth-cobalt magnet
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
WO2002034661A2 (en) 2000-10-19 2002-05-02 Henry Colombo Methods and apparatus for forming leak-proof coupling for beverage system
PL217751B1 (pl) 2001-08-03 2014-08-29 Glycart Biotechnology Ag Zastosowanie glikomodyfikowanego przeciwciała do wytwarzania kompozycji farmaceutycznej do leczenia choroby wybranej z grupy składającej się z nowotworu, małopłytkowości autoimmunologicznej w przewlekłej chorobie przeszczep przeciwko gospodarzowi i immunozależnej nabytej aplazji czysto czerwonokrwinkowej
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1641818B1 (en) 2003-07-04 2008-12-03 Affibody AB Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
NZ588860A (en) 2003-11-05 2012-03-30 Roche Glycart Ag CD20 antibodies with increased Fc receptor binding affinity and effector function
RU2402567C2 (ru) 2003-12-05 2010-10-27 Бристоль-Майерз Сквибб Компани Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2
US7527791B2 (en) 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
ES2403055T3 (es) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2437571T3 (es) 2004-11-11 2014-01-13 Theramab Llc Anticuerpos anti-CD28 superagonistas
TWI387602B (zh) 2005-02-07 2013-03-01 Roche Glycart Ag 與上皮生長因子受體（ｅｇｆｒ）結合之抗原結合分子，編碼該抗原結合分子之載體及其用途
CA2602375C (en) 2005-03-23 2018-07-24 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US7585960B2 (en) * 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
LT1976880T (lt) 2005-12-21 2016-10-10 Amgen Research (Munich) Gmbh Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea
EP1976885B1 (en) 2005-12-21 2014-12-03 Amgen Research (Munich) GmbH Pharmaceutical antibody compositions with resistance to soluble cea
AU2007333146A1 (en) 2006-12-12 2008-06-19 Idera Pharmaceuticals, Inc. Synthetic agonists of TLR9
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
EP2211885B1 (en) 2007-10-12 2015-07-29 Seattle Genetics, Inc. Combination therapy with antibody-drug conjugates
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
MX2011010166A (es) * 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
PE20121616A1 (es) 2009-12-22 2012-12-05 Roche Glycart Ag Anticuerpos anti-her3
PT2603530T (pt) 2010-08-13 2018-01-09 Roche Glycart Ag Anticorpos anti-fap e métodos de utilização
RS62238B1 (sr) 2011-02-10 2021-09-30 Roche Glycart Ag Mutantni interleukin-2 polipeptidi
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2859767C (en) 2011-12-19 2018-09-11 Synimmune Gmbh Bispecific antibody molecule and use thereof for treatment of proliferative disease
EA201590171A1 (ru) * 2012-07-09 2015-09-30 Дженентек, Инк. ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
EP2882777B1 (en) 2012-08-07 2018-10-10 Roche Glycart AG Composition comprising two antibodies engineered to have reduced and increased effector function
CA2891493C (en) 2013-02-26 2022-03-15 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
JP2016512421A (ja) * 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
TWI701261B (zh) 2013-12-17 2020-08-11 美商建南德克公司 抗cd3抗體及使用方法
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
ES2979976T3 (es) 2014-08-04 2024-09-27 Hoffmann La Roche Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
CR20170194A (es) 2014-11-14 2017-07-10 Hoffmann La Roche Moleculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf
MX2017006610A (es) 2014-11-20 2017-09-29 Hoffmann La Roche Terapia combinada de moleculas de union a antigeno biespecificas activadoras de celulas t y antagonistas de union de eje de pd-1.
EA201791121A1 (ru) 2014-11-20 2018-04-30 Ф. Хоффманн-Ля Рош Аг Активирующие т-клетки биспецифические антигенсвязывающие молекулы против folri и cd3
WO2016156291A1 (en) 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
PE20180046A1 (es) 2015-04-13 2018-01-15 Pfizer Anticuerpos terapeuticos y sus usos
CN108135968A (zh) 2015-08-28 2018-06-08 阿穆尼克斯运营公司 嵌合多肽组装体及其制备和使用方法
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
BR112018006350A2 (pt) 2015-10-02 2018-10-09 Hoffmann La Roche anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, formulação farmacêutica e uso do anticorpo
CN108026177B (zh) * 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗cd19xcd3 t细胞活化性抗原结合分子
MX2018004157A (es) 2015-10-07 2019-04-01 F Hoffmann ­La Roche Ag Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador.
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
EP3998285A1 (en) 2016-03-25 2022-05-18 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
WO2017194442A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
US20190233534A1 (en) * 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
KR102669762B1 (ko) 2016-12-19 2024-05-30 에프. 호프만-라 로슈 아게 표적화된 4-1bb(cd137) 작용물질과의 병용 요법
CA3039446A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
JP7122311B2 (ja) 2017-01-03 2022-08-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗４－１ｂｂクローン２０ｈ４．９を含む二重特異性抗原結合分子
WO2018177966A1 (en) 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Improved antigen binding receptors
EP3600408A1 (en) * 2017-03-27 2020-02-05 H. Hoffnabb-La Roche Ag Improved antigen binding receptor formats
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
MX2019011907A (es) 2017-04-04 2020-01-09 Hoffmann La Roche Nuevas moleculas de union a antigeno biespecificas capaces de unirse especificamente a cd40 y a fap.
UA128451C2 (uk) 2017-04-05 2024-07-17 Ф. Хоффманн-Ля Рош Аг Біспецифічне антитіло, яке специфічно зв'язується з pd1 і lag3
WO2018189220A1 (en) 2017-04-13 2018-10-18 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
MX2020004573A (es) 2017-11-01 2020-09-25 Hoffmann La Roche Terapia de combinacion con agonistas de ox40 dirigidos.
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
CN111182944B (zh) 2017-11-01 2022-11-22 豪夫迈·罗氏有限公司 双特异性2+1 Contorsbody
JP2021511782A (ja) 2018-01-31 2021-05-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 安定化された免疫グロブリンドメイン
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
KR20200132913A (ko) 2018-03-13 2020-11-25 에프. 호프만-라 로슈 아게 4-1bb 작용제와 항-cd20 항체의 치료 조합
AR114284A1 (es) 2018-04-13 2020-08-12 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
AU2019279084A1 (en) * 2018-06-01 2020-12-17 University Of Southern California Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
JP2021528988A (ja) 2018-07-04 2021-10-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
CN112654641A (zh) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
JP7221379B2 (ja) 2018-10-01 2023-02-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｆａｐクローン２１２を含む二重特異性抗原結合分子
US20200223925A1 (en) 2018-12-21 2020-07-16 Hoffmann-La Roche Inc. Tumor-targeted superagonistic cd28 antigen binding molecules
CN113677403A (zh) 2019-04-12 2021-11-19 豪夫迈·罗氏有限公司 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
KR20220025848A (ko) 2019-06-26 2022-03-03 에프. 호프만-라 로슈 아게 Cea 및 4-1bbl에 결합하는 항체의 융합
WO2021140130A1 (en) 2020-01-09 2021-07-15 F. Hoffmann-La Roche Ag New 4-1bbl trimer-containing antigen binding molecules
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
US12049515B2 (en) 2020-06-23 2024-07-30 Hoffmann-La Roche Inc. Agonistic CD28 antigen binding molecules targeting Her2
JP2023531067A (ja) 2020-06-25 2023-07-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子

Also Published As

Publication number Publication date
US20200199234A1 (en) 2020-06-25
AU2019410073B2 (en) 2024-08-01
CN113286821A (zh) 2021-08-20
AU2019410073A1 (en) 2021-06-10
KR20210108981A (ko) 2021-09-03
US20230416365A1 (en) 2023-12-28
JP2023021958A (ja) 2023-02-14
WO2020127618A1 (en) 2020-06-25
MY198034A (en) 2023-07-27
JP2022514343A (ja) 2022-02-10
JP2024020215A (ja) 2024-02-14
SG11202105093RA (en) 2021-06-29
UA128001C2 (uk) 2024-03-06
CL2021001603A1 (es) 2022-02-11
CL2023001092A1 (es) 2023-12-15
CN118440201A (zh) 2024-08-06
IL283811A (en) 2021-07-29
MX2021007320A (es) 2021-07-07
TW202039567A (zh) 2020-11-01
PE20211696A1 (es) 2021-09-01
US11608376B2 (en) 2023-03-21
CL2023001091A1 (es) 2023-12-15
MA54513A (fr) 2022-03-30
CA3123493A1 (en) 2020-06-25
EP3898682A1 (en) 2021-10-27
CR20210326A (es) 2021-09-10
BR112021012101A2 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
CO2021008696A2 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
CL2021000630A1 (es) Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585)
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
PH12018501419A1 (en) Pharmaceutical composition comprising bispecific antibody constructs
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
CO2023000055A2 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
UY35168A (es) Composiciones y métodos de anticuerpos de marcaje de epo
BR112016014731A2 (pt) Anticorpos anti-baff
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
CO2021007882A2 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
CO2019013718A2 (es) Anticuerpos anti-trkb